Summary
Public health interventions for respiratory virus outbreaks increasingly rely on genomic sequencing for the rapid identification of new (variant) viruses1–5. However, global sequencing efforts are unevenly distributed6–9, with some high-income countries sequencing at >100,000 times the rate of many low-income countries. Given the importance of virus genomic sequencing and substantial global disparities in sequencing capacities, there is a need for meaningful minimum sequencing targets and functional upper bounds that maximise resource efficiency1,2,8,10,11. Here, using mathematical models and analyses of data on global SARS-CoV-2 sequencing output in 2022, we show that increases in sequencing rates typical of low-income countries are >100-fold more effective at reducing time to detection of new variants than increases from rates typical of high-income countries. We find that relative to 2022 sequencing rates, establishing a minimum respiratory virus sequencing capacity of two sequences per million people per week (S/M/wk) with a two-week time from sample collection to sequence deposition in all countries, while simultaneously capping sequencing rates at 30 S/M/wk in all countries, could reduce mean time to first variant detection globally by weeks-to-months while also reducing global sequencing output by >60%. Our results show that investing in a minimum global respiratory virus sequencing capacity is far more effective at improving variant surveillance than expanding local sequencing efforts in countries with existing high-intensity respiratory virus surveillance programs and can guide rightsizing of global respiratory virus genomic surveillance infrastructure.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the European Research Council (grant number 818353).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Data on global population sizes are available from the United Nations World Population Prospects 2022 (https://population.un.org/wpp/Download/Standard/MostUsed/). Data on country GDP (https://data.worldbank.org/indicator/NY.GDP.PCAP.CD) and income classification (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups) is available from the World Bank. The Global Transnational Mobility Dataset is available from the Global Mobilities Project (https://migrationpolicycentre.eu/globalmobilities/dataset/). Metadata on global SARS-CoV-2 and seasonal influenza virus sequencing rates were extracted from GISAID (www.gisaid.org).
Code availability
Custom code and data used to generate the results in this study is publicly available at https://github.com/AMC-LAEB/genomic_surveillance_equity. Raw global epidemic simulation output is available at https://zenodo.org/records/10051237.
